The COVID-19 pandemic resulted in a worldwide effort to develop vaccines and therapeutic agents to combat SARS-CoV-2. The industry-wide lack of experience with this complex coronavirus called for novel approaches to method development and design.
PPD Laboratories’ immunochemistry department (ICD) successfully developed a suite of serology assays that are sensitive and specific. These methods provide clinical utility and granular data to support the efficacy of therapeutic interventions. Challenges to this process were numerous, including rapid turnaround time, shortages of reagents and supplies and lack of reference material to assess cross-reactivity to other coronaviruses and respiratory viruses.
The aim of this interactive webinar is to explore the process and challenges for the development of SARS-CoV-2 serology assays and to share the varied experiences and exciting results from the ICD R&D team.